Is This Common Item in Your Fridge Contributing to 180,000 Deaths Annually?

Many of the world's leading causes of death are quite obvious, but this global killer could be lurking in your refrigerator right now!

Mar 22, 2014 at 11:08AM

Global obesity rates are a growing concern with World Health Organization statistics claiming that between 1980 and 2013 obesity rates have doubled. This is a primary concern since obesity is one of a number of high-risk factors linked to cancer occurrence and a number of other diseases.

We're all probably well aware of how avoiding fatty foods is in our best health interests, but we may not be aware that this common item found in our refrigerators can potentially be linked to more than 180,000 deaths annually.

File
Source: Marcos Andre, Wikimedia Commons.

Is trouble lurking in your fridge?
According to a study authored by postdoctoral research fellow Gitanjali Singh at the Harvard School of Public Health and released last year, sugar-sweetened beverages can be linked to more than 180,000 obesity-related deaths around the world each year.

Singh's research looked at 114 different national dietary surveys covering 60% of the world's population and studied additional medical journals to get data on how sugar-sweetened beverages affected a person's risk of death around the world. Based on Singh's findings, Mexico had the highest death rate associated with sugary drinks with the U.S. coming in third out of the 35 countries examined.

Singh's findings revolve around the idea that sugar-sweetened beverages, ranging from soft drinks to energy drinks to fruit and sport beverages, induce weight-gain which has the potential to lead to obesity and the numerous complications associated with being obese, including diabetes, heart disease, and cancer.

One contention offered by the Harvard School of Public Health is that sugary beverages don't make a person feel "as full," allowing them to drink more and consume more sugar and food in general. We also have to take into account that serving sizes for beverages, such as soft drinks, have dramatically increased in size over the past six decades from 6.5 oz. to 20 oz. As the Harvard School of Public Health notes, a 20-oz. soda can have 15-18 teaspoons of sugar, which is already more than a typical person should consume in a day.

By comparison, the latest sugar consumption recommendations by WHO suggests that sugars should make up less than 10% of energy intake per day. In fact, WHO estimates that a daily intake of 5% or less, which equates to about five tablespoons of sugar, would have even more beneficial effects on the body.

Of course, not everyone agrees with Singh's research. The American Beverage Association released a statement shortly after this poster was released that the research was more about "sensationalism than science" The ABA's contention is that the author's made "a huge leap" contending that sugary beverages are the cause of death in patients where chronic diseases are the actual cause. 

The ABA's point does have its merits as diabetes and cardiovascular disease, for example, can develop in patients that aren't overweight -- and CV is still the leading cause of death in the United States. Still, obesity represents a daunting problem around the world, especially in the U.S., and tackling obesity in a number of different ways, including lowered sugar consumption, should only serve to improve global health.

Chemist

Source: PublicDomainImages, Pixabay.

How we're fighting back
Tackling obesity isn't a simple cut-and-dried operation. It necessitates improved global awareness of the disease by people and corporations, as well as a genuine desire by those consumers and businesses to do something about it. Let's have a look at some of the unique ways that businesses are fighting back against obesity, as well as some of the unique opportunities you may have as an investor to participate in the effort to shrink global waistlines.

Perhaps one of the more obvious ways to keep sugar out of our beverages, or at least dramatically reduce its consumption, is through flavor modulation. Two companies that are currently leading this charge are Senomyx (NASDAQ:SNMX) and International Flavor & Fragrances (NYSE:IFF).

Last week Senomyx received positive news from the Food and Drug Administration after it found its Sweetmyx flavor ingredient to be generally recognized as safe. With this GRAS designation PepsiCo. (NYSE:PEP), Senomyx's exclusive partner on Sweetmyx, will be able to pursue the commercialization of this new ingredient. PepsiCo. will be using Sweetmyx as a sugar substitute in a number of new low-calorie beverages which could give it an edge over its chief rival Coca-Cola. For Senomyx, commercialization through PepsiCo. could lead to explosive revenue growth potential through royalty payments.

International Flavor and Fragrances, or IFF, has a similar mode of action. Its flavor ingredients are designed to match not only the sweetness of sugar in beverages where sugar content has been reduced or potentially eliminated, it's also designed to match the mouthfeel and or consistency of a sugar product. By successfully masking any bad tastes from removing sugar IFF could wind up playing a huge role behind the curtain in reducing obesity rates.

The other way researchers are tackling obesity related to all sorts of consumable foods, including sugary beverages, is with weight control management therapies that act as an adjuvant to proper diet and exercise.

G

Source: Arena Pharmaceuticals.

The two fairly new weight control management drugs approved by the FDA are Qsymia, made by VIVUS, and Belviq, developed by Arena Pharmaceuticals (NASDAQ:ARNA). Based on the clinical trials that got both Qsymia and Belviq approved just weeks apart in 2012, Qsymia offered superior weight-loss to Belviq on a percentage basis while Belviq impressed with a more favorable safety profile. Unfortunately, neither drug has impressed investors in the early going.

Following a full year of sales, Qsymia managed to bring in just $23.7 million in revenue while Arena's Belviq brought in $16.8 million through two-and-a-half quarters. We may want to give Belviq the benefit of the doubt since it only made it to pharmacy shelves about a year after Qsymia due to a delay by the Drug Enforcement Agency in scheduling the drug, but Qsymia's performance thus far has been nothing short of disappointing

What investors and patients with a high body mass index will want to keep their eyes on is Orexigen Therapeutics (NASDAQ:OREX) whose lead weight control management drug, Contrave, is currently under review by the FDA. Contrave's weight-loss and safety data was right on par with its peers save for one key difference: it is running a multi-year 9,800-person cardiovascular outcomes study known as the Light Study. Interim results from the study demonstrated that Contrave did not increase adverse events in patients taking the drug, which may allow it to one-up Belviq and Qsymia in the safety department. The Light Study could also be the key that unlocks Contrave to be approved in Europe where Qsymia failed to gain approval and where Belviq pulled its marketing application. If there's a weight-loss management company that has an opportunity to positively impact the fight against obesity, and thus its potential side effects, I think it's Orexigen.

Is this monster stock for 2014 lurking right under your nose?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool owns shares of, and recommends Coca-Cola and PepsiCo. and has the following options: long January 2016 $37 calls on Coca-Cola and short January 2016 $37 puts on Coca-Cola. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers